Defining a molecular phenotype for benign and malignant parathyroid tumors. - Wikidata - awgldk - TriplyDB

Defining a molecular phenotype for benign and malignant parathyroid tumors.

Defining a molecular phenotype for benign and malignant parathyroid tumors.

http://www.wikidata.org/entity/Q44557302

about

Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas Parathyroid cancer.Parathyroid carcinoma arising from four-gland hyperplasia.Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.Identification of differentially expressed microRNA in parathyroid tumors Parathyromatosis or recurrent multiple parathyroid adenomas? A case report Non-functional parathyroid carcinoma: a case report and review of the literature.CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.Parathyroid tumors and related disorders.Parathyroid carcinoma: update and guidelines for management.Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.Update on parathyroid carcinoma.Molecular diagnosis of parathyroid carcinoma: a reality in the near future.Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse?Parathyromatosis: critical diagnosis regarding surgery and pathologic evaluation Atypical manifestation of parathyroid carcinoma with late-onset distant metastases.Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.A nationwide study on parathyroid carcinoma.Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis.Parathyromatosis.CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses

P2860

Q34429448-A80CE759-507B-4E47-B4B6-B4D4A3796BF9 Q34686824-4CDECE0B-9EF3-4F2F-BA10-62598DA0019F Q34792877-2455DA8A-395F-402A-B1ED-B7307A7D6DB1 Q36037109-7632B32B-F9B9-411A-9C2A-5F319659E124 Q36254236-4D267FE1-0735-4D8F-89A0-E6F3AEAE1996 Q36359062-79589BA2-DCF9-4F54-A153-7A6E8F681941 Q36838858-7ACEAA9B-830C-4AEB-8F5D-9C5FEAF3F914 Q37358248-3F0740B8-26C6-44B2-BC8F-E30DA0B0CE19 Q37860135-C7ED8134-174C-4AF9-A1E3-0D77D8F793EB Q37983468-349EB393-0BEF-4C10-A63E-5EF6A40CE2EC Q38777548-42683C80-E034-449C-8779-C798F4DF1F9F Q38784218-C74B37EE-F704-4C8E-95F6-02A0FC0F9F2C Q39670916-35F3093E-F42B-4E57-A5C1-76749592D721 Q41296038-595DF893-49D7-4164-91CB-D8D265EED65D Q41762676-BF5F4AB2-2FD7-4681-8FAB-19D722E001D4 Q46584358-4F377CCB-3388-4FCF-BE7A-0258A175CD33 Q52606764-82B1698B-725B-4EE7-8A2E-F5DC8B547C6F Q52778896-FE1E6937-8FD1-40A8-BFC2-5BC9F513BE77 Q53131281-0C8448EB-64A0-4D30-9176-2BC60EACE3F0 Q53228284-0AC90F0A-3B28-4AE4-8022-D7873D7A235E Q55119082-B1C1800D-019A-4B85-93F1-E50FA17C7775 Q57748219-EB396194-61C9-4BFD-BBD3-16560E8C39EE Q58497279-CCF378D9-9EFA-4F6F-8A85-84CD2BA4C4BA

P2860

Defining a molecular phenotype for benign and malignant parathyroid tumors.

http://www.wikidata.org/entity/Q44557302

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@en

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@nl

type

label

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@en

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@nl

prefLabel

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@en

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@nl

P1433

Q44557302-048C22AB-6B83-4FB6-868A-16058D42E012

P1476

Q44557302-7ED7B83C-7F1A-491D-8158-4B5024B0114E

P2093

Q44557302-7E08C69F-9AE2-49FA-A042-C276E14D2F74

Q44557302-8D4EEC77-562C-4E28-AA1B-6EEFBCFD14E4

Q44557302-91E7C1C6-92BA-43B4-A3F6-493C0CA44AEB

Q44557302-AA82B4CE-F467-456D-923F-21EB3C89287D

Q44557302-B7E14A88-9749-492C-AA59-430E25CEC894

Q44557302-C02BE69C-2323-434F-B591-2EDCECF270E2

Q44557302-DFFC930E-2D62-4C88-9B7A-3B64F7EE8891

P2860

Q44557302-1AE2DC70-FAC9-4273-A253-01328C325FF2

Q44557302-329B5015-3613-4DD7-8EDC-CFB9AA403C51

Q44557302-387A5898-50CF-43AC-8AA0-8F50B4CBD537

Q44557302-3A0BE7B5-ED06-483D-A36D-AFB415AAA466

Q44557302-55639C30-B6F6-46DA-B241-1C39C5AFC66F

Q44557302-6366512F-4493-48D8-8C3B-8EC8CE1BF2F0

Q44557302-66A8E997-8D75-4E78-A12A-C9D7860E0A04

Q44557302-822E518F-EB56-42CA-BE74-9A15A2A426ED

Q44557302-84386930-31A3-4FB8-895A-CAF0F69C42CC

Q44557302-8AFA1154-F75C-47FE-9324-46FF6A443D5B

P304

Q44557302-056FC605-42E2-40D7-83B2-FBA87A08BCB4

P31

Q44557302-2676047C-AA1A-4AF5-9399-6E6D175C2DFB

P356

Q44557302-5C95DDD0-6DBB-4F66-9A16-1A4A524FD6A8

P407

Q44557302-054CF04A-BE9B-422C-98FB-8E35E23678C5

P433

Q44557302-B14046D7-2C42-4A85-AE29-A116C18BB659

P478

Q44557302-4224A36A-E2C0-453B-9C61-F9BEEAD5146C

P577

Q44557302-75F3CAB7-E45B-4740-9E4F-2028519BB2F0

P698

Q44557302-FDB3C0F7-4964-421F-A1CF-95F88C9AAC1E

P356

P1433

P1476

Defining a molecular phenotype for benign and malignant parathyroid tumors.

@en

P2093

David Tacha

http://www.w3.org/2001/XMLSchema#string

Electron Kebebew

http://www.w3.org/2001/XMLSchema#string

Elham Khanafshar

http://www.w3.org/2001/XMLSchema#string

Gustavo G Fernandez-Ranvier

http://www.w3.org/2001/XMLSchema#string

Mariwil Wong

http://www.w3.org/2001/XMLSchema#string

Orlo H Clark

http://www.w3.org/2001/XMLSchema#string

Quan-Yang Duh

http://www.w3.org/2001/XMLSchema#string

P2860

HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours

Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995

HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.

Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.

Parathyromatosis: a cause for recurrent hyperparathyroidism.

Primary hyperparathyroidism: controversies in surgical management.

On the role of galectin-3 in cancer apoptosis.

Physical and functional interaction between wild-type p53 and mdm2 proteins.

Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence.

Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner.

P304

334-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24037

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19107770

http://www.w3.org/2001/XMLSchema#string